Payment overview · 2025
General Payments
$183.86
10 reported records · 7 companies
Healthcare provider profile · identity verified
Anthony Russo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · YOUNGSTOWN, OH · NPI 1366890410
Verified facts
What the public records show
CMS Open Payments records show Anthony Russo, M.D. received $183.86 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 45.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.90 | 45.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.54 | 11.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.68 | 9.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.67 | 9.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.60 | 8.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.15 | 8.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.32 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.86 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $55.36 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.54 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
200 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 513 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 383 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 332 | 98 |
| Lisinopril | Lisinopril | 262 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 76 |
| Gabapentin | Gabapentin | 221 | 59 |
| Metformin Hcl | Metformin Hcl | 208 | 60 |
| Eliquis | Apixaban | 200 | 47 |
| Omeprazole | Omeprazole | 191 | 57 |
| Losartan Potassium | Losartan Potassium | 170 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 37 |
| Simvastatin | Simvastatin | 151 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 36 |
| Sertraline Hcl | Sertraline Hcl | 130 | 38 |
| Montelukast Sodium | Montelukast Sodium | 129 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 35 |
| Methylprednisolone | Methylprednisolone | 121 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 32 |
| Furosemide | Furosemide | 100 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 23 |
| Alprazolam | Alprazolam | 87 | 22 |
| Lorazepam | Lorazepam | 83 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 19 |
| Donepezil Hcl | Donepezil Hcl | 81 | 22 |
| Ozempic | Semaglutide | 81 | 15 |
| Carvedilol | Carvedilol | 74 | 22 |
| Famotidine | Famotidine | 72 | 18 |
| Azithromycin | Azithromycin | 68 | 53 |
| Synthroid | Levothyroxine Sodium | 68 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 64 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 39 |
| Warfarin Sodium | Warfarin Sodium | 63 | 11 |
| Enalapril Maleate | Enalapril Maleate | 62 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 12 |
| Potassium Chloride | Potassium Chloride | 59 | 17 |
| Allopurinol | Allopurinol | 56 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 17 |
| Atenolol | Atenolol | 54 | 16 |
| Celecoxib | Celecoxib | 53 | 27 |
| Ibuprofen | Ibuprofen | 52 | 15 |
| Pregabalin | Pregabalin | 52 | 11 |
| Tramadol Hcl | Tramadol Hcl | 52 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 11 |
| Meclizine Hcl | Meclizine Hcl | 47 | 14 |
| Jardiance | Empagliflozin | 46 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 17 |
| Meloxicam | Meloxicam | 46 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Glimepiride | Glimepiride | 43 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 15 |
| Spironolactone | Spironolactone | 42 | 14 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 28 |
| Ezetimibe | Ezetimibe | 38 | 11 |
| Glipizide | Glipizide | 38 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 12 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Sucralfate | Sucralfate | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 11 |
| Methocarbamol | Methocarbamol | 36 | 11 |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | 11 |
| Finasteride | Finasteride | 29 | 13 |
| Prednisone | Prednisone | 29 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 22 |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Nystatin | Nystatin | 19 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.86 · 10 records | ABBVIE INC. | AIRSUPRA, CAMZYOS, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error